The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study-Reference-Cited by-同舟云学术

The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study

Published:2018-06 Issue:6 Volume:36 Page:309.e15-309.e23
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Matthes Katarina L.,Pestoni Giulia,Korol Dimitri,Van Hemelrijck Mieke,Rohrmann Sabine

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference51 articles.

1. Krebsregister der Kantone Zuerich und Zug. Jahresbericht 2016. http://www.krebsregister.usz.ch/fachwissen/Documents/Jahresbericht_Krebsregister%202016.pdf; 2017 [Accessed 2017 May 05].

2. Schweizer Krebsbulletin. http://sakk.ch/fileadmin/customer/Open_section/About_SAKK/Publications/Krebsbulletin/Schweizer_Krebsbulletin_1-2013.pdf; 2013 [Accessed 2015 20/07/15].

3. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends;Etzioni;J Natl Cancer Inst,2002

4. Causes of death in men with localized prostate cancer: a nationwide, population‐based study;Van Hemelrijck;BJU Int,2016

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Cardiovascular Risks of Radical Prostatectomy and External Beam Radiation Therapy in Early-Stage Prostate Cancer: A Comprehensive Retrospective Analysis;Annals of Surgical Oncology;2024-08-20

2. ASO Author Reflections: Evaluating Cardiovascular Mortality in Localized Treatments for Early-Stage Prostate Cancer;Annals of Surgical Oncology;2024-08-16

3. A Model‐Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk;Clinical Pharmacology in Drug Development;2024-05-17

4. Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer;Acta Oncologica;2024-03-20

5. Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open‐label, phase 2 trial;The Prostate;2024-02-04